#China #Beijing #RNA Therapeutics #Tsingke Biotech #Nucleic Acid Solutions

Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing

On July 26, 2025, Tsingke Biotech organized the 2025 Small Nucleic Acid Therapeutics Roundtable, an influential event held in Beijing that brought together over 100 prominent scientists, industry leaders, and research decision-makers. This significant gathering focused on the latest developments in RNA-based therapeutics, particularly in the synthesis, delivery methods, and pathways for commercialization of oligonucleotide therapies.

Key Highlights and Discussions

The roundtable included keynote speeches and high-profile discussions exploring the complexities and future possibilities of RNA therapeutics. A wide array of topics was addressed, which are paramount for the growth and success of this field:

• - Innovations in Structural Design: Experts shared their latest breakthroughs in nucleic acid design, demonstrating how new circular and condensed structures can enhance the stability and distribution of these drugs within biological systems.
• - Targeting Beyond the Liver: Novel delivery strategies utilizing glycosylated carriers and circular condensation mechanisms showed promise in overcoming formidable physiological barriers, such as the blood-brain barrier, thereby broadening the potential applications of oligonucleotide drugs beyond hepatic targeting.
• - Aptamer Development Advancements: Cutting-edge screening techniques were showcased, merging solid-liquid interface selection with fluorescence validation. This innovative approach aids in the efficient identification of high-affinity aptamer candidates, crucial for the development of effective therapeutics.
• - Panel Insights: A panel comprising industry thought leaders addressed several pressing issues, including the technological gap in delivery platforms in China, the significance of early-stage chemical manufacturing planning, and the strategies for navigating clinical acceptance and intellectual property risks in the evolving domestic landscape.

Tsingke Biotech's Role in Advancing Therapeutics

As the host of this vital roundtable, Tsingke Biotech outlined its continuous efforts in high-purity oligonucleotide synthesis and its commitment to facilitating the translational journey of RNA therapeutics from laboratory settings to clinical applications. A spokesperson emphasized the importance of manufacturability, regulatory readiness, and favorable delivery strategies, stating, "Oligonucleotide therapeutics are now in a crucial stage where factors like synthesis efficiency, regulatory acceptance, and delivery methods are just as critical as their molecular design.”

Furthermore, Tsingke highlighted its push towards scalable manufacturing capabilities, aimed at empowering developers in the RNA therapeutic space. The company's ongoing innovations in synthesis methods, coupled with strategic partnerships, position it as a vital connector between research advancements and real-world therapeutic applications.

Looking into the future, Tsingke Biotech advocates for a more connected landscape where innovation meets application, stating, “The next decade is pivotal for defining the contribution of oligonucleotides to precision medicine.” Tsingke remains dedicated to bridging the gap between cutting-edge research and practical solutions for therapeutic developers around the globe.

For additional insights into Tsingke Biotech's nucleic acid solutions, visit their official website at www.tsingke.com.

Conclusion

The 2025 Small Nucleic Acid Therapeutics Roundtable exemplifies Tsingke Biotech's leadership and commitment to the advancement of RNA-based therapies. As discussions around these innovative treatments evolve, Tsingke Biotech continues to play a significant role in shaping the future of healthcare through supportive infrastructure and research facilitation.